The bowel refers to the lowermost portion of the gastrointestinal (GI) tract. Structural or biochemical abnormalities associated with the bowel can give rise to a variety of disorders, with common examples including ulcerative colitis and Crohn’s disease, collectively termed inflammatory bowel disease. In the case of ulcerative colitis, there is chronic inflammation of the colon and rectum. Meanwhile in Crohn’s disease, though inflammation may occur anywhere along the gut, it most frequently manifests in the ileum.
Treatment options for inflammatory bowel disease (IBD) are evolving as knowledge of the condition is increasing. In the future, physicians may be able to offer therapy tailored to individual patients. This Learning Zone describes the background behind such advances.
Recurrent or persistent abdominal pain, diarrhoea, fatigue and loss of appetite are some of the symptoms most frequently reported by patients with bowel disorders. Treatment of bowel disorders can prove challenging; however alleviation of symptoms may be achieved through dietary alterations or pharmacological interventions.
To find out more about the diagnosis and treatment of some of the most common bowel disorders, visit our dedicated “Anti-integrins in IBD” and “Inflammatory bowel disease assessment tools” Learning Zones, with a disease overview available in our Inflammatory Bowel Disease Knowledge Centre.
Related news and insights
Galapagos NV has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca (filgotinib), a once-daily, oral, JAK1 preferential inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
Eli Lilly and Company announced new Phase II data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year.
The guideline has been condensed into two papers,[...] the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].
The goal of this consensus initiated by the European Crohn’s and Colitis Organisation [ECCO] and European Society of Colo-Proctology [ESCP] was to establish European consensus guidelines for the surgical treatment of Crohn’s disease [CD].